March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new ...
FDA
March 21, 2025
March 24, 2025 — Imperative Care, Inc. recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ...
March 24, 2025
March 11, 2025 — Caristo Diagnostics has received U.S. Food and Drug Administration (FDA) 510(k) clearance of its CaRi ...
March 11, 2025
March 3, 2025 — Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration ...
March 04, 2025
Feb. 25, 2025— GE HealthCare has delivered the first patient doses of Flyrcado (flurpiridaz F 18) injection, a unit dose ...
March 03, 2025
Feb. 4, 2025 — Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 ...
February 04, 2025
January 29, 2025 – Roche announced today that the Tina-quant Lipoprotein (a) Gen.2 Molarity assay has received 510(k) ...
February 03, 2025
Jan. 29, 2025 – Scandinavian Real Heart AB (recently aannounced that its total artificial heart, Realheart TAH, has been ...
January 30, 2025
Jan. 28, 2025 — Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular ...
January 29, 2025
Jan. 8, 2025 — Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines ...
January 08, 2025
Jan. 7, 2025 — FIRE1 recently announced it has received Breakthrough Device Designation from the U.S. Food and Drug ...
January 07, 2025
Dec. 12, 2024 — Physicians have a new treatment option for many of the sickest pediatric patients with heart failure and ...
December 18, 2024
Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...
November 25, 2024
Nov, 4, 2024 – R3 Vascular Inc. has announced that the U.S. Food and Drug Administration (FDA) granted investigational ...
November 07, 2024
Oct. 24, 2024 — Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera ...
October 30, 2024